# Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

> **NCT03412383** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College** · enrollment: 14 (estimated)

## Conditions studied

- Breast Cancer
- HER2 Gene Mutation

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT03412383
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-20
- **Primary completion:** 2019-01-25
- **Final completion:** 2019-06-25
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412383, "Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03412383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*